Chondrogenesis of Mesenchymal Stem Cell Derived form Canine Adipose Tissue

Byung-Joo Lee, MD¹, Soo-Geun Wang, MD¹, Cheol-Ju Seo, MD¹, Jin-Chun Lee, M.D¹, Jin-Sup Jung, MD² and Ryang-Hwa Lee, MD²

Department of Otolaryngology; and Department of Physiology, College of Medicine, Pusan National University,

Busan, Korea

Background and Objectives: Cartilage reconstruction is one of medical issue in otolaryngology. Tissue engineering is presently being utilized in part of cartilage repair. Sources of cells for tissue engineering are chondrocyte from mature cartilage and bone marrow mesenchymal stem cells that are able to differentiate into chondrocyte. Recent studies have shown that adipose tissue have mesenchymal stem cells which can differentiate into adipogenic, chondrogenic myogenic, osteogenic cells and neural cell in vitro. In this study, we have examined chondrogenic potential of the canine adipose tissue-derived mesenchymal stem cell (ATSC).

Materials and Methods: We harvested canine adipose tissue from inguinal area. ATSCs were enzymatically released from canine adipose tissue. Under appropriate culture conditions, ATSCs were induced to differentiate into the chondrocyte lineages using micromass culture technique. We used immunostain to type II collagen and toluidine blue stain to confirm chondrogenic differentiation of ATSCs.

Results: We could isolate ATSCs from canine adipose tissue. ATSCs expressed CD29 and CD44 which are specific surface markers of mesenchymal stem cell. ATSCs differentiated into micromass that has positive response to immunostain of type II collagen and toluidine blue stain.

Conclusion: In vitro, ATSCs differentiated into cells that have characteristic cartilage matrix molecules in the presence of lineage-specific induction factors. Adipose tissue may represent an alternative source to bone marrow-derived MSCs.

This manuscript was submitted at Korean Journal of Otolaryngology.

REFERENCES

- Isshiki N, Okamura H, Ishikawa T. Thyroplasty type 1 (lateral compression) for dysphonia due to vocal cord paralysis or atrophy. Acta Otolaryngol 1975;80:465-73.
- Iwatake H, Iida J, Minami S, et al. Transcutaneous intracordal silicon injection for unilateral vocal cord paralysis. Acta Otolaryngol Suppl 1996:522:133-7.
- 3) Arnold GE. Alleviation of aphonia or dysphonia through intracordal injection of teflon paste. Ann Otol Rhinol Laryngol 1963;39:2043-8.
- 4) Hallen L, Testad P, Sederholm E, et al. DiHA (dextranomers in hyaluronan) injections for treatment of insufficient closure of the vocal folds: early clinical experiences. Laryngoscope 2001;111:1063-7.
- 5) Ford CN, Staskowski PA, Bless DM. Autologous collagen vocal fold injection: a preliminary clinical study. Laryngoscope 1995: 105:944-8.
- 6) Reijonen B, Leivovo I, Nevalainen T, et al. Histology of injected autologous fascia in the paralysis canine vocal fold. Laryngoscope 2001;111:1068-74.
- 7) Duke SG, Salmon J, Blalock PD, et al. Fascia augmentation of the vocal fold: graft yield in the canine and preliminary clinical experience. Laryngoscope 2001;111:759-64.
- 8) Peer LA. Reconstruction of the auricular with diced cartilage grafts in a vitallium ear mold. Plast Reconstr Surg 1948; 3:653-66.
- 9) Arnold GE. Vocal rehabilitation of paralytic dysphonia: I. cartilage injection into a paralyzed vocal cord. Arch Otolaryngol 1955;62:1-17.
- 10) Zuk PA, Min Z, Hiroshi M, Jerry H, William F, Adam JK, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering 2001:7:211-28.
- 11) Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilac F. Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. Biochem Biophys Res Commun 2002;290:763-9.